Proteus Discover can help reduce the cost of healthcare by helping physicians treat their patients with chronic conditions to goal. |
|
 |
About 1 in 4 people suffer from two or more chronic conditions such as hypertension or type-2 diabetes2 |
 |
84% of U.S. healthcare spending is on patients with chronic conditions2 |
 |
More than 50% of prescribed medications are not taken as directed3 |
1Osterberg et al. J Am Coll Cardiol. 2016;67(13_S):2028. |
|
Better insights.
Better treatment.
Better care.
Proteus Discover is a Digital Medicine offering that measures medication treatment effectiveness and helps physicians improve clinical outcomes.
New!
ABILIFY MYCITE®, a Digital Medicine just granted an NDA approval by the FDA, is a drug-device combination product of Otsuka’s aripiprazole embedded with Proteus’ ingestible sensor.
Proteus Discover is a Digital Medicine offering that measures medication treatment effectiveness and helps physicians improve clinical outcomes… Learn More
New!
ABILIFY MYCITE®, a Digital Medicine just granted an NDA approval by the FDA… Read More
When Proteus Discover is activated, amazing things start to happen.
Proteus Discover is comprised of ingestible sensors, a small wearable sensor patch, an application on a mobile device and a provider portal. Once activated, Proteus Discover unlocks never-before-seen insight into patient health patterns and medication treatment effectiveness, leading to more informed healthcare decisions for everyone involved.
More engaged patients
With Proteus Discover, patients can easily monitor their medication-taking patterns on their mobile device.
Optimized therapies
Physicians have access to objective data that enables them to initiate, titrate, eliminate medication.
Improved outcomes
Health systems are able to measure treatment effectiveness and optimize therapies.
An innovation on-ramp for health systems
Proteus Discover is the world’s first Digital Medicine offering designed for health organizations searching for an efficient, patient-centric approach to measure, manage and improve the health of patient populations. Proteus Discover provides the tools needed to build efficiency and measurement into the delivery of care, and an opportunity to mitigate the high costs of uncontrolled diseases. The offering can also become an essential component of a health system’s ACO or health plan implementation strategy.
Where can Proteus Discover make the biggest impact? With high-risk populations, including patients with hypertension and diabetes. In a recent study patients with uncontrolled hypertension and diabetes who used Proteus Discover achieved significantly greater reduction in blood pressure (BP) and LDL cholesterol, and were more likely to reach their BP goal than usual care without Proteus Discover.1
Proteus Discover is the world’s first Digital Medicine offering designed for health organizations searching for an efficient, patient-centric approach to measure, manage and improve the health of patient populations. Proteus Discover provides the tools needed to build efficiency and measurement into the delivery of care, and an opportunity to mitigate the high costs of uncontrolled diseases. The offering can also become an essential component of a health system’s ACO or health plan implementation strategy.
Where can Proteus Discover make the biggest impact? With high-risk populations, including patients with hypertension and diabetes. In a recent study patients with uncontrolled hypertension and diabetes who used Proteus Discover achieved significantly greater reduction in blood pressure (BP) and LDL cholesterol, and were more likely to reach their BP goal than usual care without Proteus Discover.1
About 1 in 4 people suffer from two or more chronic conditions such as hypertension or type-2 diabetes2
Unlocking actionable insights for physicians and care teams
Proteus Discover removes the guesswork around diagnosis and treatment by providing insight into patient health and medication treatment effectiveness. The Discover report for healthcare providers is easy and quick to read, smoothly integrating into current treatment workflows.
With evidence in hand, physicians and their care teams are better equipped to:
- Quickly decode patterns around medication adherence and patient behaviors
- Make objective decisions about when to initiate, titrate, and eliminate medicine
- Optimize treatment therapies and get patients to goal faster
- Engage in richer, more meaningful conversations with patients based on clear, objective data
Proteus Discover removes the guesswork around diagnosis and treatment by providing insight into patient health and medication effectiveness. The Discover report for healthcare providers is easy and quick to read, smoothly integrating into current treatment workflows.
With evidence in hand, physicians and their care teams are better equipped to:
- Quickly decode patterns around medication adherence and patient behaviors
- Make objective decisions about when to initiate, titrate, and eliminate medicine
- Optimize treatment therapies and get patients to goal faster
- Engage in richer, more meaningful conversations with patients based on clear, objective data
Putting patients in control of their health
Proteus Discover helps patients get better, faster — by providing easy access to important data around their medication-taking and health patterns, such as activity, rest and heart rate. With information in hand, patients are able to make more informed healthcare decisions and become more engaged with their overall health.
Once activated by the patient, Proteus Discover:
- Provides visibility into medication-taking patterns
- Increases connectivity to the patient’s care team
- Allows for more relevant conversations with healthcare providers
- Makes doctor visits more productive
Proteus Discover is easy to use and seamlessly integrates into a patient’s daily routine. In a recent study, more than 80% of patients reported that Proteus Discover facilitated more helpful conversations with their healthcare professionals and improved their healthcare experience.
Proteus Discover helps patients get better, faster — by providing easy access to important data around their medication-taking and health patterns, such as activity, rest and heart rate. With information in hand, patients are able to make more informed healthcare decisions and become more engaged with their overall health.
Once activated by the patient, Proteus Discover:
- Provides visibility into medication-taking patterns
- Increases connectivity to the patient’s care team
- Allows for more relevant conversations with healthcare providers
- Makes doctor visits more productive
Proteus Discover is easy to use and seamlessly integrates into a patient’s daily routine. In a recent study, more than 80% of patients reported that Proteus Discover facilitated more helpful conversations with their healthcare professionals and improved their healthcare experience.
How does Proteus Discover work?
Proteus Discover consists of an ingestible sensor the size of a grain of sand, a small wearable sensor patch, an application on a mobile device and a provider portal. The patient activates Proteus Discover by taking medication with an ingestible sensor. Once the ingestible sensor reaches the stomach, it transmits a signal to the patch worn on the torso. A digital record is sent to the patient’s mobile device and then to the Proteus cloud where with the patient’s permission, healthcare providers and caregivers can access it via their portal. The patch also measures and shares patient activity and rest.
The Pill
The ingestible sensor is the result of innovative manufacturing processes that combine high-volume semiconductor and pharmaceutical technology. It’s made of elements found in a typical diet and has been approved for marketing by the U.S. Food and Drug Administration and CE marked in Europe.
The ingestible sensor is the result of innovative manufacturing processes that combine high-volume semiconductor and pharmaceutical technology. It’s made of elements found in a typical diet and has been approved for marketing by the U.S. Food and Drug Administration and CE marked in Europe.
The Patch
Developed by a team of patient-centered designers and engineers, the patch is an FDA-approved sensor that tracks medication taking, steps, activity, rest and heart rate. The patch was designed for comfort and ease of use, and is refined by years of user research.
Developed by a team of patient-centered designers and engineers, the patch is an FDA-approved sensor that tracks medication taking, steps, activity, rest and heart rate. The patch was designed for comfort and ease of use, and is refined by years of user research.
The Discover App
The Discover App is designed to help patients keep track of their medications, steps, activity, rest, heart rate, blood pressure and weight. Patients can also set multiple medication-taking schedules and receive notifications.
The Discover App is designed to help patients keep track of their medications, steps, activity, rest, heart rate, blood pressure and weight. Patients can also set multiple medication-taking schedules and receive medication reminders.
The Discover Portal
The Discover Portal allows physicians to quickly drill down into specific patient data points and allocate care team resources to those patients who need it most. The information in the portal provides insight that helps healthcare professionals determine the best treatment, using an easy-to-read printed report. These reports may also be used in conversations with the patient to enable shared decision-making and improve physician-patient relationships.
The Discover Portal allows physicians to quickly drill down into specific patient data points and allocate care team resources to those patients who need it most. The information in the portal provides insight that helps healthcare professionals determine the best treatment, using an easy-to-read printed report. These reports may also be used in conversations with the patient to enable shared decision-making and improve physician-patient relationships.
Transforming care with Digital Medicine
Medication non-adherence leads to uncontrolled health conditions, excess hospitalizations, emergency room visits and office visits, resulting in additional cost to the U.S. healthcare system of $290 billion annually.2,3
Non-adherence is multifactorial and must be addressed by understanding the underlying cause (e.g. side effects, lack of understanding of the disease, and dosing schedule). Providers lack accurate, timely adherence data necessary to diagnose non-adherence and its root cause and allow the patient and provider to respond quickly to poor adherence.4
Randomized, IRB-monitored, clinical trials and real-world use of our Digital Medicine offering Proteus Discover, have demonstrated significantly improved and sustained outcomes.
- 2 http://www.nehi.net/writable/publication_files/file/pa
_issue_brief_final.pdf. Accessed on 31 May 2016 - 3 JAMA 2013;310(24):2611-2
- 4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711878/. Accessed April 2017.
Cardiovascular Diseases
-
In the U.S. around 75 million people have hypertension or high blood pressure1
-
About half of patients are not at blood pressure (BP) goal2
-
For every increase of 20 mm Hg in systolic BP or 10 mm Hg in diastolic BP, the risk of ischemic heart disease and stroke doubles3
-
The direct annual medical costs in the U.S. associated with hypertension and its complications were $130.7 billion in 2010 and are expected to increase to $389 billion by 20304
-
About 29.1 million people in the U.S. have diabetes a major risk factor for heart disease and stroke5 this includes an estimated 8.1 million people who are undiagnosed
-
In 2012, diabetes cost the U.S. $176 billion in direct medical costs and $69 billion in indirect costs or lost productivity5
- 1 https://www.cdc.gov/bloodpressure/facts.htm
- 2 Circulation 2011 Mar 1;123(8):933-44.
- 3 Lancet 2002; 360: 1903-1913.
- 4 Circulation. 2011 Mar 1;123(8):933-44.
- 5 https://professional.diabetes.org/sites/professional.diabetes.org/files/media/fast_facts_8-2017_pro_3.pdf. Accessed April 2018.
-
Proteus Discover helps providers identify the root cause for uncontrolled disease and facilitate medical decision-making while also helping promote patient medication adherence and engagement, leading to improved clinical outcomes.
UK Hypertension Registry Study
Proteus helped healthcare providors determine which patients needed medication titration versus those that needed adherence counseling.- 144 patients with uncontrolled hypertension used Proteus for two weeks
- Identified root cause of uncontrolled hypertension in all patients Mean systolic BP decreased by 10 mm Hg and diastolic BP decreased by 5 mm Hg
UK Pharmacist Real World Evaluation
Proteus identified specific reasons for uncontrolled hypertension enabling pharmacist-led interventions to control BP.- 39 patients at 15 community pharmacies used Proteus for two weeks
- 91% of pharmacists noted Proteus enabled them to provide data- based counseling and recommendations
-
US Hypertension and Diabetes Cluster-Randomized, Controlled Study
With Proteus Discover 98% of patients with uncontrolled hypertension and diabetes who failed to achieve goal while on therapy with at least 2 anti-hypertensives and 1 diabetes medicine achieved their BP targets within 90 days.- 109 subjects with uncontrolled type 2 diabetes (A1C > 7%) and hypertension (systolic BP ≥ 140 mm Hg) across 13 sites used Proteus Discover with Digital Medicines or received usual care
- After 4 weeks, Discover users had greater reductions in:
• Systolic BP (reduction of 22 mm Hg vs. 13 mm Hg for usual care).
• Hemoglobin A1C (-0.5% vs. a gain of 0.2% for usual care) in those with baseline ≥8%
- • LDL cholesterol (-37 mg/dL vs. -4 mg/dL for usual care) in those with baseline LDL 70 mg/dL
- Discover users received more medical interventions (e.g. medication changes, counseling, and lifestyle coaching)
- More than 90% of Discover users agreed that Discover was easy to learn to use and helped them with taking medicines more regularly
-
ISPOR Health Economics Study
Estimated $1020 – $1260 per patient per year of value for payers when Proteus is used by patients with comorbid hypertension, type 2 diabetes, and hypercholesterolemia.- Estimated cost offsets, direct medical cost savings (eg. medical complications avoided) and increased revenue (due to higher quality ratings) from using Proteus Discover for a typical U.S. healthcare plan
- One-year time horizon with one month of Proteus use based on results from the UK Hypertension Registry Study. Value greater if considering the data from the US Hypertension and Diabetes cluster-randomized controlled study
Infectious Disease
-
New oral Hepatitis C drugs must be taken as prescribed to achieve a cure
-
Improving adherence reduces treatment failures and the need to re-treat, as well as increasing efficiencies in monitoring
-
DOT is resource intensive, time consuming and represents the largest single cost of TB treatment
-
For tuberculosis (TB) directly observed therapy (DOT) is recommended to ensure a cure and mitigate spread and resistance
-
Wireless observed therapy (WOT) with Proteus Discover represents a more efficient option for TB therapy monitoring1
- 1 TB HEOR Study. International Journal of Tuberc Lung Dis
2012;16(11):1498–1504. http://www.ingentaconnect.com/content
one/iuatld/ijtld/2012/00000016/00000011/art00014
-
Hepatitis C Study
Proteus Discover helped to optimize adherence necessary to ensure a cure in Hepatitis C infected patients.UCSD Tuberculosis Study
Proteus captured 48% more medication ingestions than gold-standard, directly observed, therapy.- 28-patient study with interim analysis of 27 patients who took a digitized combination of sofosbuvir and ledipasvir (co-encapsulated with the Proteus ingestible sensor pill)
- Average ingestion adherence was 94%
- Facilitated, targeted and timely intervention in non-adherent patients
- In a satisfaction survey, 92% of patients agreed Proteus Discover was easy to use in their daily routine, and 88% agreed it helped them understand the importance of taking their medications regularly
- Mean detection accuracy of 98.7% (range 94% to 100%) with digitized combination of rifampin and isoniazid
- Rated easy to use by 90% of patients
- Demonstrated bioequivalence of co-encapsulated digital medicine with non-digitized form
-
TB Health Economic Study
Potential savings of Wirelessly Observed Therapy (WOT, Proteus) compared with Directly Observed Therapy (DOT) for tuberculosis treatment.- Compared costs associated with WOT to DOT (3 or 7 days per week) for tuberculosis treatment
- 7-day DOT costs were $3472 vs. $1273 for WOT
- Personnel costs associated with DOT explain much of the difference
- Reduction in costs allows providers to treat 1.4 to 2.7 times as many patients with WOT
Performance and Safety
-
More than 60 studies conducted since 2004
-
FDA clearance was granted in 2012 in a de novo category
-
Evidence covers a variety of populations across disease states, disease severity, gender, age, and race/ethnicity
-
Extensive Accuracy and Safety Profile
Established in more than 490 participants in over 10 years.
- 20,993 ingestions in 412 study participants:
• 97.3% detection rate of the ingestible sensor
• 100% correct identification (no false positives)
• 4 subjects (1%) reported nausea or vomiting - 6,407 patch-use days in 492 volunteers:
• 61 (12.4%) reported a self-limited rash localized to the patch placement site - No serious adverse events related to the ingestible sensor or patch were reported in these clinical studies
- 20,993 ingestions in 412 study participants:
-
Summary of Robust Pre-clinical and Early Clinical Studies
Underpin the performance and safety of the Proteus technology.Review of Three Studies
Demonstrates accuracy and safety of the Proteus technology across different patient populations (hypertension, tuberculosis, and heart failure).- Changes in gastric pH (from 1.6 to 7) or chloride or pepsin concentration did not impact ingestible sensor conductivity
- Ingestible sensor is safe; tested for chemical, electrical, and mechanical safety and toxicology
- Positive detection accuracy is 99.1% (95% confidence interval: 97.3% – 99.7%)
- BMI ranged from 16.0 to 56.8 kg/m2 in these studies
- 1628 ingestions in 81 subjects
- Overall accuracy was 97.6% (95% confidence interval: 96.7% – 98.3%)
- No adverse events occurred in relation to the sensor
- Minor skin irritation (pruritis) in 23 subjects (28%)
- Moderate skin irritation (contact dermatitis) in 2 subjects (2%)
Proteus in the News
The world has discovered Proteus Digital Health. Learn how our people, our customers and our partnerships are making an impact by reading our latest news releases.
View News Stories
